Substance / Medication

Muromonab-CD3

Overview

Active Ingredient
muromonab-CD3
RxNorm CUI
42405

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Muromonab-CD3 therapy for refractory rejections after liver transplantation: a single-center experience during two decades in Japan.
Ueda Daisuke, Hori Tomohide, Nguyen Justin H et al. · J Hepatobiliary Pancreat Sci · 2010
PMID: 20458505Observational
Comparative study of muromonab-CD3 (OKT3) versus daclizumab (Zenapax) in cardiac transplantation at our center.
Campos A, Lage E, Hinojosa R et al. · Transplant Proc · 2005
PMID: 15866669Observational
Peripheral T-cell lymphoma immunophenotype in a patient with a history of Muromonab-CD3 therapy: A case report and a diagnostic dilemma.
Hoffmann Joerg, Klameth Andreas, Russwurm Martin et al. · Cytometry B Clin Cytom · 2022
PMID: 33955673Case Report
Muromonab-CD3 for the successful treatment of early chronic rejection after pediatric liver transplantation: report of a case.
Hori Tomohide, Nguyen Justin H, Uemoto Shinji · Surg Today · 2011
PMID: 21431500Case Report
OKT3 (muromonab-CD3) associated hepatitis in a kidney transplant recipient.
Go Michael R, Bumgardner Ginny L · Transplantation · 2002
PMID: 12131696Case Report
Muromonab-CD3-induced neurotoxicity: report of two siblings, one of whom had subsequent cyclosporin-induced neurotoxicity.
Thaisetthawatkul P, Weinstock A, Kerr S L et al. · J Child Neurol · 2001
PMID: 11732768Case Report
Anaphylactoid reaction to muromonab-CD3 in a pediatric renal transplant recipient.
Berkowitz R J, Possidente C J, McPherson B R et al. · Pharmacotherapy · 2000
PMID: 10641983Case Report
Platelet procoagulant activity induced in vivo by muromonab-CD3 infusion in uremic patients.
Lozano M, Oppenheimer F, Cofan F et al. · Thromb Res · 2001
PMID: 11755950Other
Reversible sensorineural hearing loss following administration of muromonab-CD3 (OKT3) for cadaveric renal transplant immunosuppression.
Hartnick C J, Smith R V, Tellis V et al. · Ann Otol Rhinol Laryngol · 2000
PMID: 10651411Other

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Muromonab-CD3 (substance)
SNOMED CT
109137000
UMLS CUI
C0085379
RxNorm CUI
42405

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.